![Einat Galamidi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 8 440 $ op 31-05-2026
Einat Galamidi currently works at Enlivex Therapeutics Ltd., as Chief Medical Officer from 2025.
Dr. Galamidi also formerly worked at Gamida Cell Ltd., as Vice President-Clinical Development.
Dr. Galamidi received her doctorate degree from The Hebrew University of Jerusalem.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 18-03-2026 | 10.420 ( 0% ) | 8 440 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ENLIVEX | Hoofd Techniek/Wetenschap/O&O | 01-02-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| GAMIDA CELL LTD. | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 3 |
|---|---|
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gamida Cell Ltd.
 Gamida Cell Ltd. Pharmaceuticals: MajorHealth Technology Engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases | Health Technology |
Enlivex Therapeutics Ltd.
 Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
Kies MarketScreener 
